Newsletter | November 4, 2024

Best of October: Top 5 Insights In Clinical Supply Chain & Logistics

Clinical Supply Leader

TOP 5 INSIGHTS IN CLINICAL SUPPLY CHAIN & LOGISTICS  

OCTOBER EDITION

#1 - Exploring Sanofi R&D's Batch Monitoring Initiative

To manage both fast project ramp-up times and delivery predictability, Sanofi sets global lead time targets for its R&D production, testing, and release processes. Discover how its Amsterdam site has successfully implemented an approach that led to a swift and reliable reduction of lead times below target within six months. 

#2 - Hidden Benefits Of Clinical Forecasting & Supply Planning Solutions

Many pharmaceutical companies today rely on spreadsheets not just for forecasting demand and planning production but also for the entire supply chain. Discover how transitioning to cloud-based supply chain management solutions can provide enhanced data integrity, scalability, real-time collaboration, and advanced analytics.

#3 - Massive Data, More Decentralization Drive Updates To ISPE GAMP Guide

ISPE has recognized the need for an updated guide that discusses and makes recommendations for risk-based systems validations related to Good Clinical Practice. Author Frank Henrichmann describes the changing clinical data environment and details updates that will support the work of various clinical trial stakeholders. 

#4 - The Importance Of Selecting Packaging Components: A Practical Checklist For Emerging Biotechs

Regardless of a company’s size, recognizing the importance of packaging development and prioritizing its role in drug development early on can help you proactively identify events that could delay your timelines. Explore five key considerations in selection components for your injectable drug product.

#5 - What's In The Leukopak Matters For Cell Therapy Manufacturing

More than 500 clinical trials are currently underway exploring cellular therapies derived from healthy donor immune cells. Without high-quality leukopaks from high-quality donors, the widespread success of advanced cellular therapies is not possible.